COA ↓

Product

COA Doc

SYN-2618

99.2% Purity SYN-2618 Research Grade HPLC Verified

5-Amino-1MQ

NNMT Inhibitor · Research Grade

Select Strength — 10mg

$125.00

C₇H₉N₃ MW: 135.17 g/mol CAS: 1239366-16-5

In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.2%

HPLC Purity

Lot Number SYN-2618-5A1MQ

Test Date March 2026

Labeled 100 mg/cap

Actual 100.2 mg

99.4%

HPLC Purity

Lot Number SYN-2517-5A1MQ

Test Date May 2026

Labeled 100 mg/cap

Actual 100.4 mg

Research Data

KEY FINDINGS

🧬

+30%

NAD+ Elevation in Adipose

Intracellular NAD+ increase following NNMT inhibition in fat cells

🔬

−20%

Body Weight in Obese Mouse Model

At 10 mg/kg for 10 weeks — Neelakantan H et al., 2019

✅

99.2%

HPLC-Verified Purity

Current batch SYN-2618, third-party accredited lab

💊

Oral

Bioavailable Capsule Form

Orally active small molecule — no reconstitution required

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔥 NAD+ Restoration

NNMT Inhibition — 30% NAD+ Increase in Adipose

Neelakantan et al. demonstrated that selective NNMT inhibition by 5-Amino-1MQ increased intracellular NAD+ by 30%, activated SIRT1 by 44%, and reduced adipocyte size by 28% in vitro — while reducing body weight by 20% in a high-fat diet mouse model over 10 weeks.

🔬 30% NAD+ increase + 44% SIRT1 activation — upstream NNMT inhibition produces broader metabolic effects than direct NAD+ precursor supplementation alone.

PMID 30611999 — Biochem. Pharmacol.

30 %

NAD+ Elevation via NNMT Inhibition in Adipose Tissue

5-Amino-1MQ inhibits NNMT (Nicotinamide N-methyltransferase) — the enzyme that consumes SAM-e and NAD+ precursors in adipose tissue. Inhibition increases intracellular NAD+ by ~30%, activates SIRT1, and promotes fat cell shrinkage with metabolic rate elevation in preclinical models.

Metabolic Effects — 5-Amino-1MQ in Adipose Cell Cultures

NAD+ elevation +30%

SIRT1 activity increase +44%

Adipocyte size reduction −28%

Source: Neelakantan H et al., Biochem. Pharmacol., 2019

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2618-5A1MQ

Specification	Value
CAS Number	1239366-16-5
Molecular Formula	C₇H₉N₃
Molecular Weight	135.17 g/mol
Purity (HPLC)	99.2%
Appearance	Oral capsules — 60 capsule bottle
Solubility	Oral — encapsulated form
Storage	Room temperature 15–25°C · Away from moisture and light
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

20 %

Body Weight Reduction in Obese Mouse Model (10 wks)

5-Amino-1MQ −20%

Control −4%

Comparative Activity Profile

5-Amino-1MQ NMN (precursor)

Observed Adverse Indicators

Cytotoxicity in vitro

None

Off-target methyltransferase

None

SAM-e pathway modulation

Expected

Hepatotoxicity markers

None

⚠️ Theoretical Concern

Preclinical Data Only — No Human Clinical Trials Completed

All published 5-Amino-1MQ efficacy and safety data is from in vitro cell culture and rodent models. Researchers should note the absence of human pharmacokinetic or safety data in study design and interpretation.

No cytotoxicity, genotoxicity, or hepatotoxicity in published in vitro models
Selective for NNMT — not a broad methyltransferase inhibitor; SAM-e pathway effects are targeted
All preclinical data: no human clinical trial data available — this is a research compound with limited translational context

Peer-Reviewed Literature

RESEARCH CITATIONS

Biochemical Pharmacology

Selective NNMT Inhibition by 5-Amino-1MQ in Adipose Tissue

2019 Neelakantan H et al.

PMID 30611999 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.

5-Amino-1MQ

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

NNMT Inhibition — 30% NAD+ Increase in Adipose

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

Preclinical Data Only — No Human Clinical Trials Completed

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS